Technical Analysis for CYCCP - Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Grade Last Price % Change Price Change
D 18.40 0.00% 0.00
CYCCP closed unchanged on Monday, March 18, 2024, on 0 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%

   Recent Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock Description

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Inflammatory Diseases Cancer Cell Autoimmune And Inflammatory Disease Cyclacel Cell Cycle Cyclin Dependent Kinase Dna Synthesis Human Cancers PLK1 Cdk Inhibitor Cell Cycle Checkpoint Cyclin Dependent Kinase 2 Sapacitabine Seliciclib

Is CYCCP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.2
52 Week Low 5.2096
Average Volume 1,399
200-Day Moving Average 14.17
50-Day Moving Average 18.86
20-Day Moving Average 18.55
10-Day Moving Average 19.06
Average True Range 1.14
RSI (14) 47.09
ADX 13.84
+DI 24.41
-DI 19.74
Chandelier Exit (Long, 3 ATRs) 18.06
Chandelier Exit (Short, 3 ATRs) 20.06
Upper Bollinger Bands 20.24
Lower Bollinger Band 16.86
Percent B (%b) 0.46
BandWidth 18.23
MACD Line -0.01
MACD Signal Line 0.11
MACD Histogram -0.1159
Fundamentals Value
Market Cap 229.95 Million
Num Shares 12.5 Million
EPS -2.05
Price-to-Earnings (P/E) Ratio -8.99
Price-to-Sales 99.96
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.40
Resistance 3 (R3) 18.40 18.40 18.40
Resistance 2 (R2) 18.40 18.40 18.40 18.40
Resistance 1 (R1) 18.40 18.40 18.40 18.40 18.40
Pivot Point 18.40 18.40 18.40 18.40 18.40
Support 1 (S1) 18.40 18.40 18.40 18.40 18.40
Support 2 (S2) 18.40 18.40 18.40 18.40
Support 3 (S3) 18.40 18.40 18.40
Support 4 (S4) 18.40